Key Laboratory of Natural Medicines of the Changbai Mountain, Affifiliated Ministry of Education, College of Pharmacy, Yanbian University, Yanji, Jilin, 133002, China.
Key Laboratory of Natural Medicines of the Changbai Mountain, Affifiliated Ministry of Education, College of Pharmacy, Yanbian University, Yanji, Jilin, 133002, China.
Eur J Med Chem. 2024 Nov 15;278:116813. doi: 10.1016/j.ejmech.2024.116813. Epub 2024 Aug 30.
Tumor proliferation and metastasis are intricately linked to blood vessel formation, with vascular endothelial growth factor (VEGF) playing a pivotal role in orchestrating angiogenesis throughout tumor progression. Pseudolaric acid B (PAB) has emerged as a potent inhibitor of tumor cell proliferation, migration, and angiogenesis. In efforts to enhance its efficacy, 37 derivatives of PAB were synthesized and assessed for their capacity to suppress VEGF secretion in SiHa cells under hypoxic conditions. Notably, majority of these derivatives exhibited significant inhibition of VEGF protein secretion without inducing cytotoxicity. Among them, compound M2 displayed the most potent inhibitory activity, with an IC value of 0.68 μM, outperforming the lead compound PAB (IC = 5.44 μM). Compound M2 not only curbed the migration and angiogenesis of HUVECs under hypoxic conditions but also hindered the invasion of SiHa cells. Mechanistic investigations unveiled that compound M2 may impede the accumulation and nuclear translocation of hypoxia-inducible factor 1α (HIF-1α) in SiHa cells, thereby downregulating VEGF expression. This inhibitory effect on HIF-1α was corroborated by experiments utilizing the protease inhibitor MG-132 and protein synthesis inhibitor CHX, indicating that compound M2 diminishes HIF-1α levels by reducing its synthesis. Furthermore, compound M2 was observed to modulate the PI3K/AKT/mTOR and MAPK signaling pathways in tumor cells, thereby regulating HIF-1α translation and synthesis. In vivo studies demonstrated that compound M2 exhibited low toxicity and effectively curbed tumor growth. Immunohistochemistry analyses validated that compound M2 effectively suppressed the expression of HIF-1α and VEGF in tumor tissues, underscoring its potential as a promising therapeutic agent for targeting tumor angiogenesis.
肿瘤的增殖和转移与血管生成密切相关,血管内皮生长因子(VEGF)在肿瘤进展过程中协调血管生成中起着关键作用。白头翁素 B(PAB)已成为一种有效的肿瘤细胞增殖、迁移和血管生成抑制剂。为了提高其疗效,合成了 37 种 PAB 衍生物,并评估了它们在缺氧条件下抑制 SiHa 细胞分泌 VEGF 的能力。值得注意的是,这些衍生物中的大多数都能显著抑制 VEGF 蛋白的分泌,而不会诱导细胞毒性。其中,化合物 M2 表现出最强的抑制活性,IC 值为 0.68 μM,优于先导化合物 PAB(IC = 5.44 μM)。化合物 M2 不仅抑制了缺氧条件下 HUVEC 的迁移和血管生成,还抑制了 SiHa 细胞的侵袭。机制研究表明,化合物 M2 可能会阻止 HIF-1α 在 SiHa 细胞中的积累和核转位,从而下调 VEGF 的表达。用蛋白酶抑制剂 MG-132 和蛋白质合成抑制剂 CHX 进行的实验证实了对 HIF-1α 的这种抑制作用,表明化合物 M2 通过减少其合成来降低 HIF-1α 的水平。此外,观察到化合物 M2 调节肿瘤细胞中的 PI3K/AKT/mTOR 和 MAPK 信号通路,从而调节 HIF-1α 的翻译和合成。体内研究表明,化合物 M2 表现出低毒性,有效抑制肿瘤生长。免疫组织化学分析验证了化合物 M2 有效地抑制了肿瘤组织中 HIF-1α 和 VEGF 的表达,突出了其作为一种有前途的肿瘤血管生成治疗剂的潜力。